GET THE APP

From chemoprevention to identification of potential therapeutic targets and biomarkers for breast cancer
..

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

From chemoprevention to identification of potential therapeutic targets and biomarkers for breast cancer


4th World Congress on Cancer Science & Therapy

October 20-22, 2014 DoubleTree by Hilton Hotel Chicago-North Shore Conference Center, USA

Somya Shanmuganathan, Allal Ouhtit, Ishita Gupta, Hamad Al-Riyami and Madhwa Raj

Accepted Abstracts: J Cancer Sci Ther

Abstract :

Over the years, several phyto-compounds have been extensively used in Complementary Alternative Medicine (CAM) studies, individually and often at higher doses to kill cancer cells. Based on the combination and synergism theory, we had previously demonstrated that a combination of Resveratrol and Indole-3-Carbinol synergized and killed a maximum number of Breast Cancer cells. In the present study, we have tested various combinations of 10 well known phytochemicals, used at bioavailable levels, for their effect on cell growth and proliferation of the MDA-MB-231; breast cancer (BC) cell line and MCF-10A; normal breast epithelium as control cell line. The results revealed a super combination of 7phyto-compounds(7SC), that synergized and induced 100% clearance of the BC cells but did notaffect the normal breast epithelial cells. Next, in order to understand the underlying molecular mechanisms of this ?synergism? effect, microarray analysis will be conducted on themRNA collected from the 7SCtreated and control cells at 12 and 24 hour time points. Ongoing in vivo experiments aim to evaluate the efficacy of the 7SC phyto-compound treatment in preventing tumor growth using xenograft mouse BC model, and further validate the functional relevance of these genes in BC cell growth and survival. The data supports our hypothesis that the 7SC could be used in CAM as a dietary supplement approach against BC, and further identify genes that have the potential to serve as biomarkers and gene candidate to guide the design of appropriate anti-BC therapeutic strategies.

Biography :

Somya Shanmuganathan is currently pursuing her third year PhD in Genomics of Breast Cancer at the Sultan Qaboos University, Oman. Prior to her PhD, she completed her Master of Business (Merit) at the Australian National University (Australia), Master of Biotechnology at the University of Queensland (Australia) and Master of Science in Applied Microbiology at the VIT University (India). She has been a reviewer for a number of articles in several reputed international journals and is currently involved in several breast cancer research works.

Google Scholar citation report
Citations: 3968

Cancer Science & Therapy received 3968 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward